Arkolith/Insider Trading/ETON/Form 4

Riedel Norbert G

DirectorEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed Jan 14, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Grant(A)12K—$0286K
Jan 12, 2026Grant(A)8K—$0294K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-001301) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML